Holen Sie sich die Stockscreener-App
49.43
4.33%
2.12
Handel nachbörslich:
49.45
0.02
+0.04%
Schlusskurs vom Vortag:
$47.31
Offen:
$48.09
24-Stunden-Volumen:
753.34K
Relative Volume:
0.65
Marktkapitalisierung:
$1.47B
Einnahmen:
$442.68M
Nettoeinkommen (Verlust:
$-77.81M
KGV:
-18.52
EPS:
-2.6684
Netto-Cashflow:
$-28.65M
1W Leistung:
+17.16%
1M Leistung:
-27.97%
6M Leistung:
-70.20%
1J Leistung:
-31.06%
1-Tages-Spanne:
$46.80
$50.38
1-Wochen-Bereich:
$40.86
$50.38
52-Wochen-Spanne:
$32.21
$170.87
Genedx Holdings Corp Stock (WGS) Company Profile
Firmenname
Genedx Holdings Corp
Sektor
Branche
Telefon
888-729-1206
Adresse
333 LUDLOW STREET, STAMFORD
Compare WGS vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
49.43 | 1.40B | 442.68M | -77.81M | -28.65M | -2.6684 |
TMO
Thermo Fisher Scientific Inc
|
448.27 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.86 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.15 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
338.72 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.09 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-09 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-05-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-10 | Eingeleitet | Craig Hallum | Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
Alle ansehen
Genedx Holdings Corp Aktie (WGS) Neueste Nachrichten
WGS stock slumps after hours as firm predicts lower test volume for year - MSN
GeneDx a new overweight at Piper Sandler on rare diseases testing market - MSN
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34% - The Motley Fool
Prosight Management Acquires $42.72 Million Stake in GeneDx Holdings - Intellectia AI
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34% - The Motley Fool
Casdin, Meister disclose sizable GeneDx (WGS) ownership positions - Stock Titan
WGS News | GENEDX HOLDINGS CORP (NASDAQ:WGS) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Reach Out - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp.WGS - PR Newswire
Is GeneDx Stock a Buys After a Company Director Purchased Over 350,000 Shares? - Yahoo Finance
Casdin Partners master fund buys $21.5 million in GeneDx stock By Investing.com - Investing.com South Africa
Casdin Partners master fund buys $21.5 million in GeneDx stock - Investing.com India
Casdin-linked funds add 500K GeneDx (WGS) shares in open-market buys - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
GeneDx Holdings (WGS) price target decreased by 32.59% to 98.94 - MSN
Barrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities Fraud - marketscreener.com
GeneDx Holdings Corp. (WGS) Securities Fraud InvestigationLevi & Korsinsky - Morningstar
GeneDx Holdings Corp.Class A Common Stock (NQ: WGS - The Chronicle-Journal
GeneDx (WGS) 10K Form and Latest SEC Filings 2026 - MarketBeat
GeneDx faces securities fraud probe after missing revenue targets and stock plunges 49%. - Pluang
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Law firm investigates GeneDx after shares plunge 50% on weak earnings and lowered guidance - Pluang
Bragar Eagel & Squire, P.C. is Investigating GeneDx - GlobeNewswire
WGS SHAREHOLDER ALERT: Investors Encouraged to Contact - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Does GENEDX HOLDINGS (WGS) Have the Potential to Rally 26.17% as Wall Street Analysts Expect? - MSN
GeneDx Holdings Insider Bought Shares Worth $13,765,345, According to a Recent SEC Filing - marketscreener.com
A Look At GeneDx Holdings (WGS) Valuation After Q1 2026 Reset And Securities Investigation - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdin - The National Law Review
(WGS) Risk Channels and Responsive Allocation - Stock Traders Daily
Comerica Bank Sells 29,753 Shares of GeneDx Holdings Corp. $WGS - MarketBeat
GeneDx Fraud Probes And Guidance Cut Put Valuation Gap In Focus - simplywall.st
Number of shareholders of GeneDx Holdings Corp. – NASDAQ:WGS - TradingView
A Look At GeneDx Holdings (WGS) Valuation After Earnings Miss Guidance Cut And Securities Investigation - Yahoo Finance
GeneDx Holdings (WGS) upgraded to strong buy: Here's what you should know - MSN
UBS Group AG Decreases Stake in GeneDx Holdings Corp. $WGS - MarketBeat
Corvex management, director Keith Meister buy $13.7m GeneDx stock By Investing.com - Investing.com South Africa
Corvex management, director Keith Meister buy $13.7m GeneDx stock - Investing.com India
Corvex-linked funds boost GeneDx (WGS) stake with 351K-share open-market buy - Stock Titan
Casdin and Meister report 12% and 17.9% GeneDx (WGS) stakes - Stock Titan
GeneDx (NASDAQ:WGS) Shares Up 6.9%Still a Buy? - MarketBeat
GeneDx WGS Slides On Guidance Cut As Insiders Buy The Dip - StocksToTrade
GeneDx expects $475M-$490M 2026 revenue as it targets at least 30% exome/genome volume growth - MSN
GeneDx Q1 2026 misses targets; lower-margin genomic tests slow growth, but turnaround potential remains. - Pluang
Finanzdaten der Genedx Holdings Corp-Aktie (WGS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Genedx Holdings Corp-Aktie (WGS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Casdin Capital, LLC | Director |
May 18 '26 |
Buy |
42.55 |
175,000 |
7,446,547 |
3,182,164 |
| Casdin Capital, LLC | Director |
May 20 '26 |
Buy |
43.81 |
140,000 |
6,132,854 |
3,507,164 |
| Meister Keith A. | Director |
May 13 '26 |
Buy |
39.09 |
165,000 |
6,449,983 |
4,598,297 |
| Meister Keith A. | Director |
May 14 '26 |
Buy |
39.39 |
140,000 |
5,514,790 |
4,738,297 |
| Meister Keith A. | Director |
May 15 '26 |
Buy |
38.91 |
46,273 |
1,800,571 |
4,784,570 |
| Meister Keith A. | Director |
May 07 '26 |
Buy |
37.86 |
533,758 |
20,207,189 |
3,761,908 |
| Meister Keith A. | Director |
May 11 '26 |
Buy |
39.29 |
500,000 |
19,642,789 |
4,433,297 |
| Meister Keith A. | Director |
May 08 '26 |
Buy |
40.59 |
171,389 |
6,956,751 |
3,933,297 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Apr 29 '26 |
Option Exercise |
0.00 |
3,874 |
0 |
95,388 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Apr 29 '26 |
Sale |
65.19 |
2,172 |
141,595 |
93,216 |
1.43%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):